Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor

Lucia Altucci, Aurélie Rossin, Oliver Hirsch, Angela Nebbioso, Dominique Vitoux, Emmanuelle Wilhelm, Fabien Guidez, Mariacarla De Simone, Ettore Mariano Schiavone, David Grimwade, Arthur Z Zelent, Hugues De Thé, Hinrich Gronemeyer

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Apart from PML-retinoic acid receptor-α (RARα) acute promyelocytic leukemia all other acute myeloid leukemias (AML) are unresponsive to retinoid differentiation therapy. However, elevating the levels of cyclic AMP (cAMP) confers onto retinoid X receptor (RXR)-selective agonists ("rexinoids") the ability to induce terminal granulocyte differentiation and apoptosis of all-trans retinoic acid-resistant and insensitive AML cells and patients' blasts. Protein kinase A activation leads to corepressor release from the RAR subunit of the RAR-RXR heterodimer, resulting in "desubordination" of otherwise silent RXR, which acquires transcriptional competence in response to cognate ligands. Rexinoid-cAMP induction of endogenous RARβ is blunted in mouse embryo fibroblasts lacking RARs, but reintroduction of exogenous RARα reestablishes responsiveness, thus confirming that the RARα-RXR heterodimer is the rexinoid mediator. The apoptogenic effect of this treatment involves enhanced expression of the death receptor DR5 and its cognate ligand, tumor necrosis factor-related apoptosis inducing ligand, both of which are known to induce apoptosis in a tumor cell-selective manner and lead to the activation of initiator caspases. Immunohistochemistry confirmed induction of tumor necrosis factor-related apoptosis inducing ligand and DR5 in AML patient blasts cultured ex vivo. AML patients' blasts responded to rexinoid-cAMP combination treatment with induction of maturation and apoptosis, independent of karyotype, immunophenotype, and French-American-British classification status. Clonogenic assays revealed complete inhibition of blast clonogenicity in four out of five tested samples. Our results suggest that despite the genetic, morphologic, and clinical variability of this disease, the combination of rexinoids and cAMP-elevating drugs, such as phosphodiesterase inhibitors, might lead to a novel therapeutic option for AML patients by inducing a tumor-selective death pathway.

Original languageEnglish (US)
Pages (from-to)8754-8765
Number of pages12
JournalCancer Research
Volume65
Issue number19
DOIs
StatePublished - Oct 1 2005
Externally publishedYes

Fingerprint

Core Binding Factor alpha Subunits
Retinoid X Receptors
Retinoic Acid Receptors
Cyclic AMP-Dependent Protein Kinases
Acute Myeloid Leukemia
Apoptosis
Cyclic AMP
Ligands
Neoplasms
Tumor Necrosis Factor-alpha
Initiator Caspases
Co-Repressor Proteins
Death Domain Receptors
Acute Promyelocytic Leukemia
Aptitude
Phosphodiesterase Inhibitors
Retinoids
Myeloid Cells
Therapeutics
Tretinoin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor. / Altucci, Lucia; Rossin, Aurélie; Hirsch, Oliver; Nebbioso, Angela; Vitoux, Dominique; Wilhelm, Emmanuelle; Guidez, Fabien; De Simone, Mariacarla; Schiavone, Ettore Mariano; Grimwade, David; Zelent, Arthur Z; De Thé, Hugues; Gronemeyer, Hinrich.

In: Cancer Research, Vol. 65, No. 19, 01.10.2005, p. 8754-8765.

Research output: Contribution to journalArticle

Altucci, L, Rossin, A, Hirsch, O, Nebbioso, A, Vitoux, D, Wilhelm, E, Guidez, F, De Simone, M, Schiavone, EM, Grimwade, D, Zelent, AZ, De Thé, H & Gronemeyer, H 2005, 'Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor', Cancer Research, vol. 65, no. 19, pp. 8754-8765. https://doi.org/10.1158/0008-5472.CAN-04-3569
Altucci, Lucia ; Rossin, Aurélie ; Hirsch, Oliver ; Nebbioso, Angela ; Vitoux, Dominique ; Wilhelm, Emmanuelle ; Guidez, Fabien ; De Simone, Mariacarla ; Schiavone, Ettore Mariano ; Grimwade, David ; Zelent, Arthur Z ; De Thé, Hugues ; Gronemeyer, Hinrich. / Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor. In: Cancer Research. 2005 ; Vol. 65, No. 19. pp. 8754-8765.
@article{e726166dd56943ec93023013f17f395c,
title = "Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor",
abstract = "Apart from PML-retinoic acid receptor-α (RARα) acute promyelocytic leukemia all other acute myeloid leukemias (AML) are unresponsive to retinoid differentiation therapy. However, elevating the levels of cyclic AMP (cAMP) confers onto retinoid X receptor (RXR)-selective agonists ({"}rexinoids{"}) the ability to induce terminal granulocyte differentiation and apoptosis of all-trans retinoic acid-resistant and insensitive AML cells and patients' blasts. Protein kinase A activation leads to corepressor release from the RAR subunit of the RAR-RXR heterodimer, resulting in {"}desubordination{"} of otherwise silent RXR, which acquires transcriptional competence in response to cognate ligands. Rexinoid-cAMP induction of endogenous RARβ is blunted in mouse embryo fibroblasts lacking RARs, but reintroduction of exogenous RARα reestablishes responsiveness, thus confirming that the RARα-RXR heterodimer is the rexinoid mediator. The apoptogenic effect of this treatment involves enhanced expression of the death receptor DR5 and its cognate ligand, tumor necrosis factor-related apoptosis inducing ligand, both of which are known to induce apoptosis in a tumor cell-selective manner and lead to the activation of initiator caspases. Immunohistochemistry confirmed induction of tumor necrosis factor-related apoptosis inducing ligand and DR5 in AML patient blasts cultured ex vivo. AML patients' blasts responded to rexinoid-cAMP combination treatment with induction of maturation and apoptosis, independent of karyotype, immunophenotype, and French-American-British classification status. Clonogenic assays revealed complete inhibition of blast clonogenicity in four out of five tested samples. Our results suggest that despite the genetic, morphologic, and clinical variability of this disease, the combination of rexinoids and cAMP-elevating drugs, such as phosphodiesterase inhibitors, might lead to a novel therapeutic option for AML patients by inducing a tumor-selective death pathway.",
author = "Lucia Altucci and Aur{\'e}lie Rossin and Oliver Hirsch and Angela Nebbioso and Dominique Vitoux and Emmanuelle Wilhelm and Fabien Guidez and {De Simone}, Mariacarla and Schiavone, {Ettore Mariano} and David Grimwade and Zelent, {Arthur Z} and {De Th{\'e}}, Hugues and Hinrich Gronemeyer",
year = "2005",
month = "10",
day = "1",
doi = "10.1158/0008-5472.CAN-04-3569",
language = "English (US)",
volume = "65",
pages = "8754--8765",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor

AU - Altucci, Lucia

AU - Rossin, Aurélie

AU - Hirsch, Oliver

AU - Nebbioso, Angela

AU - Vitoux, Dominique

AU - Wilhelm, Emmanuelle

AU - Guidez, Fabien

AU - De Simone, Mariacarla

AU - Schiavone, Ettore Mariano

AU - Grimwade, David

AU - Zelent, Arthur Z

AU - De Thé, Hugues

AU - Gronemeyer, Hinrich

PY - 2005/10/1

Y1 - 2005/10/1

N2 - Apart from PML-retinoic acid receptor-α (RARα) acute promyelocytic leukemia all other acute myeloid leukemias (AML) are unresponsive to retinoid differentiation therapy. However, elevating the levels of cyclic AMP (cAMP) confers onto retinoid X receptor (RXR)-selective agonists ("rexinoids") the ability to induce terminal granulocyte differentiation and apoptosis of all-trans retinoic acid-resistant and insensitive AML cells and patients' blasts. Protein kinase A activation leads to corepressor release from the RAR subunit of the RAR-RXR heterodimer, resulting in "desubordination" of otherwise silent RXR, which acquires transcriptional competence in response to cognate ligands. Rexinoid-cAMP induction of endogenous RARβ is blunted in mouse embryo fibroblasts lacking RARs, but reintroduction of exogenous RARα reestablishes responsiveness, thus confirming that the RARα-RXR heterodimer is the rexinoid mediator. The apoptogenic effect of this treatment involves enhanced expression of the death receptor DR5 and its cognate ligand, tumor necrosis factor-related apoptosis inducing ligand, both of which are known to induce apoptosis in a tumor cell-selective manner and lead to the activation of initiator caspases. Immunohistochemistry confirmed induction of tumor necrosis factor-related apoptosis inducing ligand and DR5 in AML patient blasts cultured ex vivo. AML patients' blasts responded to rexinoid-cAMP combination treatment with induction of maturation and apoptosis, independent of karyotype, immunophenotype, and French-American-British classification status. Clonogenic assays revealed complete inhibition of blast clonogenicity in four out of five tested samples. Our results suggest that despite the genetic, morphologic, and clinical variability of this disease, the combination of rexinoids and cAMP-elevating drugs, such as phosphodiesterase inhibitors, might lead to a novel therapeutic option for AML patients by inducing a tumor-selective death pathway.

AB - Apart from PML-retinoic acid receptor-α (RARα) acute promyelocytic leukemia all other acute myeloid leukemias (AML) are unresponsive to retinoid differentiation therapy. However, elevating the levels of cyclic AMP (cAMP) confers onto retinoid X receptor (RXR)-selective agonists ("rexinoids") the ability to induce terminal granulocyte differentiation and apoptosis of all-trans retinoic acid-resistant and insensitive AML cells and patients' blasts. Protein kinase A activation leads to corepressor release from the RAR subunit of the RAR-RXR heterodimer, resulting in "desubordination" of otherwise silent RXR, which acquires transcriptional competence in response to cognate ligands. Rexinoid-cAMP induction of endogenous RARβ is blunted in mouse embryo fibroblasts lacking RARs, but reintroduction of exogenous RARα reestablishes responsiveness, thus confirming that the RARα-RXR heterodimer is the rexinoid mediator. The apoptogenic effect of this treatment involves enhanced expression of the death receptor DR5 and its cognate ligand, tumor necrosis factor-related apoptosis inducing ligand, both of which are known to induce apoptosis in a tumor cell-selective manner and lead to the activation of initiator caspases. Immunohistochemistry confirmed induction of tumor necrosis factor-related apoptosis inducing ligand and DR5 in AML patient blasts cultured ex vivo. AML patients' blasts responded to rexinoid-cAMP combination treatment with induction of maturation and apoptosis, independent of karyotype, immunophenotype, and French-American-British classification status. Clonogenic assays revealed complete inhibition of blast clonogenicity in four out of five tested samples. Our results suggest that despite the genetic, morphologic, and clinical variability of this disease, the combination of rexinoids and cAMP-elevating drugs, such as phosphodiesterase inhibitors, might lead to a novel therapeutic option for AML patients by inducing a tumor-selective death pathway.

UR - http://www.scopus.com/inward/record.url?scp=25444495618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444495618&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-04-3569

DO - 10.1158/0008-5472.CAN-04-3569

M3 - Article

VL - 65

SP - 8754

EP - 8765

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 19

ER -